Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants
NCT ID: NCT06708520
Last Updated: 2025-05-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1
Total Enrollment
48 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-11-21
Study Completion Date
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to assess the PK, tolerability, and safety of rupatadine (10 mg) and its active metabolites in participants with renal impairment compared to matched control participants with normal renal function.
The study duration will be up to 40 days, including Screening, Baseline, Study Period, and EOS visit assessments.
Rupatadine 10 mg tablet will be administered as single dose.
The study duration will be up to 40 days, including Screening, Baseline, Study Period, and EOS visit assessments.
Rupatadine 10 mg tablet will be administered as single dose.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics and Safety of Rupatadine in Participants With Hepatic Impairment Compared to Control Participants.
NCT06736340
Hepatic Impairment
COMPLETED
PHASE1
Study on the Effect and Mechanism of Lupatadine Fumarate in the Treatment of Allergic Rhinitis
NCT06709092
Allergic Rhinitis
RECRUITING
NA
Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria
NCT00199238
URTICARIA
TERMINATED
PHASE2
Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria
NCT01605487
Cold Contact Urticaria
COMPLETED
PHASE2
Efficacy and Safety of Rupatadine 10 and 20 Mg in Chronic Idiopathic Urticaria
NCT00199251
Urticaria
TERMINATED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is an open-label, non-randomized, parallel group study comparing the PK after administration of a single 10 mg dose of rupatadine to participants with renal impairment with matched control participants with normal renal function (matched in terms of gender, age, and body weight).
For each participant, the study visits will consist of a Screening Period (Day -28 to Day -2), a Baseline evaluation (Day -1), a single dose treatment period (Day 1) and an End of Study (EOS) Visit (Day 12 for subjects with renal impairment and Day 8 for subjects with normal real function). Additionally, from Day 2 to EOS participants will go back to the clinic for blood drawing according to schedule.
Participants who meet the eligibility criteria at Screening and Baseline will be enrolled into the study.
All Baseline safety evaluation results must be reviewed prior to dosing. Participants will be domiciled at the clinic from Day -1 until 24 hours after dosing on Day 1 (Day 2).
On Day 1, participants will receive a single dose of rupatadine 10 mg after an overnight fast of 10 hours and will continue to fast for 4 hours post-dose.
Participants with renal impairment will undergo sequential PK sampling over the following 264 hours along with other safety assessments. Participants with normal renal function will undergo sequential PK sampling over the following 144 hours along with other safety assessments.
The participant groups will be consecutively enrolled into the study. Enrollment of participants with mild, moderate, and severe renal impairment will be staggered, so that dosing of participants with mild renal impairment will be started first. Dosing of the next group will be started only after evaluation of blood PK, safety and tolerability data until 72 hours post dose of at least six participants with renal impairment from the previous group and after the assessment of safety and tolerability results are judged to be satisfactory by the Safety Committee.
An EOS assessment will occur 7 days after the administration of rupatadine in the participants with normal renal function and 11 days after in renal impaired participants.
The total study duration, including Screening, Baseline, Study Period, and EOS assessments, is up to approximately 40 days.
For each participant, the study visits will consist of a Screening Period (Day -28 to Day -2), a Baseline evaluation (Day -1), a single dose treatment period (Day 1) and an End of Study (EOS) Visit (Day 12 for subjects with renal impairment and Day 8 for subjects with normal real function). Additionally, from Day 2 to EOS participants will go back to the clinic for blood drawing according to schedule.
Participants who meet the eligibility criteria at Screening and Baseline will be enrolled into the study.
All Baseline safety evaluation results must be reviewed prior to dosing. Participants will be domiciled at the clinic from Day -1 until 24 hours after dosing on Day 1 (Day 2).
On Day 1, participants will receive a single dose of rupatadine 10 mg after an overnight fast of 10 hours and will continue to fast for 4 hours post-dose.
Participants with renal impairment will undergo sequential PK sampling over the following 264 hours along with other safety assessments. Participants with normal renal function will undergo sequential PK sampling over the following 144 hours along with other safety assessments.
The participant groups will be consecutively enrolled into the study. Enrollment of participants with mild, moderate, and severe renal impairment will be staggered, so that dosing of participants with mild renal impairment will be started first. Dosing of the next group will be started only after evaluation of blood PK, safety and tolerability data until 72 hours post dose of at least six participants with renal impairment from the previous group and after the assessment of safety and tolerability results are judged to be satisfactory by the Safety Committee.
An EOS assessment will occur 7 days after the administration of rupatadine in the participants with normal renal function and 11 days after in renal impaired participants.
The total study duration, including Screening, Baseline, Study Period, and EOS assessments, is up to approximately 40 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Renal Impairment
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Phase 1, single dose, open-label, parallel group
Primary Study Purpose
OTHER
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Renal impairement mild
Group Type
EXPERIMENTAL
Rupatadine
Intervention Type
DRUG
10 mg tablets
Renal impairement moderate
Group Type
EXPERIMENTAL
Rupatadine
Intervention Type
DRUG
10 mg tablets
Renal impairement severe
Group Type
EXPERIMENTAL
Rupatadine
Intervention Type
DRUG
10 mg tablets
Renal normal functions
Group Type
EXPERIMENTAL
Rupatadine
Intervention Type
DRUG
10 mg tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rupatadine
10 mg tablets
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Pafinur
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Participants with normal renal function and participants with mild, moderate, or severe renal impairment who meet the following criteria will be considered eligible to participate in the clinical study:
1. Participant understands the study procedures and agrees to participate in the study by giving written informed consent prior to any study-mandated procedure.
2. Able to communicate well with the Investigator, to understand and comply with the study requirements.
3. Willing to comply with study restrictions stated in Section 5.3 (lifestyle considerations).
4. Male or female Caucasian subjects, between 18 and 75 years (inclusive) of age.
5. Body mass index (BMI) is between 18 to 35 kg/m2 at Screening.
6. Women of childbearing potential (WoCBP) must have a negative serum pregnancy test at Screening, a negative urine pregnancy test on Day -1, and agree to consistently and correctly use (from 30 days prior to dosing, during the entire study, and for at least 30 days after dosing), a highly effective method of contraception (i.e., failure rate of \< 1%) (Section 10.4 \[Appendix 4\]). Such methods include:
\- Hormonal contraceptives: combined (estrogen- and progesterone-containing) contraception associated with inhibition of ovulation using oral, intravaginal, or transdermal route of administration.
Note: If a hormonal contraceptive is used, it must be initiated at least 30 days before dosing.
* Intrauterine device.
* Intrauterine hormone-releasing system.
* Bilateral tubal occlusion.
* Vasectomized partner, provided that the partner is the sole sexual partner and that the vasectomized partner has received medical assessment of the surgical success.
* Sexual abstinence, defined as refraining from heterosexual intercourse from 30 days prior to dosing up to at least 30 days after dosing, if this is the preferred and usual lifestyle of the subject.
WoCBP must also agree not to donate ova from the time of informed consent until 30 days after dosing
7. Women of non-childbearing potential (WoNCBP), i.e., postmenopausal (defined as 12 consecutive months with no menses without an alternative medical cause, confirmed by a follicular stimulating hormone \[FSH\] test), with previous bilateral salpingectomy, bilateral salpingo-oophorectomy or hysterectomy, or with premature ovarian failure (confirmed by a specialist), XY genotype, Turner syndrome, uterine agenesis (Section 10.4 \[Appendix 4\]).
8. Male participants are infertile, vasectomized (who has received medical assessment of the surgical success) or must agree to abstain from, or to use a condom, during heterosexual intercourse with a woman of childbearing potential (Section 10.4 \[Appendix 4\]).
9. Male participants must agree not to donate sperm, from the time of informed consent until 30 days after dosing.
10. Negative test results for anti-Human Immunodeficiency virus 1 and 2 antibodies (anti-HIV-1Ab and anti-HIV-2Ab), Hepatitis B surface antigen (HBsAg) and anti-Hepatitis Cvirus antibodies (anti-HCVAb).
11. Participant agrees to refrain from consuming grapefruit juice, grapefruits, and grapefruitcontaining products from at least 7 days before the dose administration, and until the EOS Visit.
12. Able to tolerate venipuncture
For participants with mild, moderate, or severe renal impairment, the following criteria must be met in addition:
13. Participants with impaired renal function should be hemodynamically stable.
14. Diagnosis of chronic (\> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in renal function) renal impairment.
15. Estimated GFR must range from:
1. 15-29 mL/min (severe renal impairment) or
2. 30-59 mL/min (moderate renal impairment) or
3. 60-89 mL/min (mild renal impairment) determined by the Cockcroft-Gault equation, at the Screening Visit.
16. Stable concomitant medications for at least 21 days prior to dosing and up to the EOS visit.
17. Systolic blood pressure (SBP) 100-180 mmHg, diastolic blood pressure (DBP) 50-105 mmHg and pulse rate 60-100 bpm (inclusive), measured on the same arm, after 5 min in the supine position at Screening and Baseline.
For participants with normal renal function, the following criteria must be met in addition:
18. No clinically relevant diseases captured in medical history at Screening.
19. No clinically relevant abnormalities on physical examination at Screening and Baseline.
20. No clinically relevant abnormalities on clinical laboratory tests at Screening.
21. Normal renal function confirmed by estimated creatinine clearance (eCLcr) ≥ 90 mL/min, as determined by the Cockcroft-Gault equation, at Screening.
22. Weight within ±15% to his/her matched participant(s) enrolled in the study.
23. Biological sex matched to his/her matched participant(s) enrolled in the study.
24. Age within ±10 years to his/her matched participant(s) enrolled in the study.
25. Normal BP measured on the same arm, after 5 min in the supine position at Screening and Baseline defined as:
* SBP 90-140 mmHg, DBP 60-90 mmHg, and pulse rate 60-100 bpm (inclusive) for subjects \< 65 years of age.
* SBP 95-160 mmHg, DBP 65-95 mmHg, and pulse rate 60-100 bpm (inclusive) for subjects ≥ 65 years of age.
1. Participant understands the study procedures and agrees to participate in the study by giving written informed consent prior to any study-mandated procedure.
2. Able to communicate well with the Investigator, to understand and comply with the study requirements.
3. Willing to comply with study restrictions stated in Section 5.3 (lifestyle considerations).
4. Male or female Caucasian subjects, between 18 and 75 years (inclusive) of age.
5. Body mass index (BMI) is between 18 to 35 kg/m2 at Screening.
6. Women of childbearing potential (WoCBP) must have a negative serum pregnancy test at Screening, a negative urine pregnancy test on Day -1, and agree to consistently and correctly use (from 30 days prior to dosing, during the entire study, and for at least 30 days after dosing), a highly effective method of contraception (i.e., failure rate of \< 1%) (Section 10.4 \[Appendix 4\]). Such methods include:
\- Hormonal contraceptives: combined (estrogen- and progesterone-containing) contraception associated with inhibition of ovulation using oral, intravaginal, or transdermal route of administration.
Note: If a hormonal contraceptive is used, it must be initiated at least 30 days before dosing.
* Intrauterine device.
* Intrauterine hormone-releasing system.
* Bilateral tubal occlusion.
* Vasectomized partner, provided that the partner is the sole sexual partner and that the vasectomized partner has received medical assessment of the surgical success.
* Sexual abstinence, defined as refraining from heterosexual intercourse from 30 days prior to dosing up to at least 30 days after dosing, if this is the preferred and usual lifestyle of the subject.
WoCBP must also agree not to donate ova from the time of informed consent until 30 days after dosing
7. Women of non-childbearing potential (WoNCBP), i.e., postmenopausal (defined as 12 consecutive months with no menses without an alternative medical cause, confirmed by a follicular stimulating hormone \[FSH\] test), with previous bilateral salpingectomy, bilateral salpingo-oophorectomy or hysterectomy, or with premature ovarian failure (confirmed by a specialist), XY genotype, Turner syndrome, uterine agenesis (Section 10.4 \[Appendix 4\]).
8. Male participants are infertile, vasectomized (who has received medical assessment of the surgical success) or must agree to abstain from, or to use a condom, during heterosexual intercourse with a woman of childbearing potential (Section 10.4 \[Appendix 4\]).
9. Male participants must agree not to donate sperm, from the time of informed consent until 30 days after dosing.
10. Negative test results for anti-Human Immunodeficiency virus 1 and 2 antibodies (anti-HIV-1Ab and anti-HIV-2Ab), Hepatitis B surface antigen (HBsAg) and anti-Hepatitis Cvirus antibodies (anti-HCVAb).
11. Participant agrees to refrain from consuming grapefruit juice, grapefruits, and grapefruitcontaining products from at least 7 days before the dose administration, and until the EOS Visit.
12. Able to tolerate venipuncture
For participants with mild, moderate, or severe renal impairment, the following criteria must be met in addition:
13. Participants with impaired renal function should be hemodynamically stable.
14. Diagnosis of chronic (\> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in renal function) renal impairment.
15. Estimated GFR must range from:
1. 15-29 mL/min (severe renal impairment) or
2. 30-59 mL/min (moderate renal impairment) or
3. 60-89 mL/min (mild renal impairment) determined by the Cockcroft-Gault equation, at the Screening Visit.
16. Stable concomitant medications for at least 21 days prior to dosing and up to the EOS visit.
17. Systolic blood pressure (SBP) 100-180 mmHg, diastolic blood pressure (DBP) 50-105 mmHg and pulse rate 60-100 bpm (inclusive), measured on the same arm, after 5 min in the supine position at Screening and Baseline.
For participants with normal renal function, the following criteria must be met in addition:
18. No clinically relevant diseases captured in medical history at Screening.
19. No clinically relevant abnormalities on physical examination at Screening and Baseline.
20. No clinically relevant abnormalities on clinical laboratory tests at Screening.
21. Normal renal function confirmed by estimated creatinine clearance (eCLcr) ≥ 90 mL/min, as determined by the Cockcroft-Gault equation, at Screening.
22. Weight within ±15% to his/her matched participant(s) enrolled in the study.
23. Biological sex matched to his/her matched participant(s) enrolled in the study.
24. Age within ±10 years to his/her matched participant(s) enrolled in the study.
25. Normal BP measured on the same arm, after 5 min in the supine position at Screening and Baseline defined as:
* SBP 90-140 mmHg, DBP 60-90 mmHg, and pulse rate 60-100 bpm (inclusive) for subjects \< 65 years of age.
* SBP 95-160 mmHg, DBP 65-95 mmHg, and pulse rate 60-100 bpm (inclusive) for subjects ≥ 65 years of age.
Exclusion Criteria
Participants with normal renal function and participants with mild, moderate, or severe renal impairment who meet one or more of the following criteria will not be considered eligible to participate in the clinical study:
1. Pregnant or lactating women.
2. Participant is unlikely to comply with the protocol requirements, instructions and study related restrictions; e.g., uncooperative attitude, inability to return for the EOS Visit and improbability of completing the clinical study.
3. Any psychological, emotional problems, any disorders or resultant therapy that is likely to invalidate informed consent, or limit the ability of the participant to comply with the protocol requirements
4. History of hypersensitivity to rupatadine, desloratadine or any of the excipients, or to medicinal products with similar chemical structures.
5. History of clinically significant lactose, galactose, or fructose intolerance.
6. Any clinically relevant acute or chronic disease which could jeopardize the safety of the participant or impact the validity of the study results.
7. Veins unsuitable for intravenous puncture on either arm (e.g., veins that are difficult to locate, access or puncture; veins with a tendency to rupture during or after puncture).
8. Participation in another clinical trial with an experimental drug within 2 months or 5 halflives (whichever is longer) before the Screening or in more than 2 clinical studies within 1 year prior to Screening.
9. History or presence of clinically significant angioedema.
10. Use of caffeine-containing beverages exceeding 800 mg per day (Section 5.3.2) at Screening.
11. Nicotine consumption (e.g., smoking, nicotine patch, nicotine chewing gum, or electronic cigarettes) from 48 h prior to Baseline (Day -1) until discharge from confinement (Day 2).
12. Positive test result for urine alcohol and drugs of abuse (amphetamines, benzodiazepines, cannabinoids, cocaine and opiates) at Screening and Baseline.
Note: Subjects receiving stable treatment of methadone and benzodiazepines will be allowed to be enrolled in the study even if the urine drug screen test is positive.
13. History of heart, kidney or liver transplantation.
14. History of stroke, chronic seizures, or major neurological disorder.
15. Active malignant neoplastic disease or carcinoma (including leukemia, lymphoma, malignant melanoma), or myeloproliferative disease, regardless of the time since treatment.
16. Intake of any creatine supplement from Screening to EOS.
17. Use of any of the following 2 weeks prior to investigational medicinal product (IMP) administration or 5 half-lives, whichever is longer:
1. Enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism (e.g., azole antifungals \[ketoconazole, itraconazole, fluconazole, Posaconazole, voriconazole\], macrolide antibiotics \[erythromycin, clarithromycin\], diltiazem, human immunodeficiency virus (HIV) protease inhibitors, nefazodone, rifampicin, phenytoin, dexamethasone, troglitazone, and barbiturates)
2. CYP3A4 substrates with a narrow therapeutic index (e.g. ciclosporin, tacrolimus, sirolimus, everolimus, cisapride)
3. Desloratadine
18. Clinically significant abnormalities on ECG repolarization (QTcF \> 450 ms in males and \>470 ms in females) at Screening.
19. Loss of 250 mL or more blood within 3 months prior to screening.
For participants with mild, moderate or severe renal impairment the additional criteria must not be met:
20. Fluctuating or rapidly deteriorating renal function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of renal impairment within the Screening Period.
21. Participants requiring dialysis.
22. History or clinical evidence of any disease (except for renal impairment) and/or existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism or excretion of rupatadine, and/or the ability to complete the study.
For participants with normal renal function, the additional criteria must not be met:
23. History or presence of a clinically relevant abnormality in any organ system, that is incapacitating, requires hospitalization, or in the opinion of the investigator makes the participant ineligible for enrollment in the study.
24. History or clinical evidence of any disease and/or existence of any surgical or medical condition that might have interfered with the absorption, distribution, metabolism, or excretion of rupatadine (appendectomy and herniotomy are allowed, cholecystectomy is not allowed).
25. Intake of any prescribed medication (including vaccines) including over-the-counter (OTC) medication (including herbal and dietary supplements such as St John's Wort, homeopathic preparations, vitamins and minerals) that could affect the outcome of the study as judged by the Investigator, within 14 days before the administration of the IMP or less than 5 times the half-life of that medication, whichever is longer (excluding contraceptives and hormone replacement therapy).
1. Pregnant or lactating women.
2. Participant is unlikely to comply with the protocol requirements, instructions and study related restrictions; e.g., uncooperative attitude, inability to return for the EOS Visit and improbability of completing the clinical study.
3. Any psychological, emotional problems, any disorders or resultant therapy that is likely to invalidate informed consent, or limit the ability of the participant to comply with the protocol requirements
4. History of hypersensitivity to rupatadine, desloratadine or any of the excipients, or to medicinal products with similar chemical structures.
5. History of clinically significant lactose, galactose, or fructose intolerance.
6. Any clinically relevant acute or chronic disease which could jeopardize the safety of the participant or impact the validity of the study results.
7. Veins unsuitable for intravenous puncture on either arm (e.g., veins that are difficult to locate, access or puncture; veins with a tendency to rupture during or after puncture).
8. Participation in another clinical trial with an experimental drug within 2 months or 5 halflives (whichever is longer) before the Screening or in more than 2 clinical studies within 1 year prior to Screening.
9. History or presence of clinically significant angioedema.
10. Use of caffeine-containing beverages exceeding 800 mg per day (Section 5.3.2) at Screening.
11. Nicotine consumption (e.g., smoking, nicotine patch, nicotine chewing gum, or electronic cigarettes) from 48 h prior to Baseline (Day -1) until discharge from confinement (Day 2).
12. Positive test result for urine alcohol and drugs of abuse (amphetamines, benzodiazepines, cannabinoids, cocaine and opiates) at Screening and Baseline.
Note: Subjects receiving stable treatment of methadone and benzodiazepines will be allowed to be enrolled in the study even if the urine drug screen test is positive.
13. History of heart, kidney or liver transplantation.
14. History of stroke, chronic seizures, or major neurological disorder.
15. Active malignant neoplastic disease or carcinoma (including leukemia, lymphoma, malignant melanoma), or myeloproliferative disease, regardless of the time since treatment.
16. Intake of any creatine supplement from Screening to EOS.
17. Use of any of the following 2 weeks prior to investigational medicinal product (IMP) administration or 5 half-lives, whichever is longer:
1. Enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism (e.g., azole antifungals \[ketoconazole, itraconazole, fluconazole, Posaconazole, voriconazole\], macrolide antibiotics \[erythromycin, clarithromycin\], diltiazem, human immunodeficiency virus (HIV) protease inhibitors, nefazodone, rifampicin, phenytoin, dexamethasone, troglitazone, and barbiturates)
2. CYP3A4 substrates with a narrow therapeutic index (e.g. ciclosporin, tacrolimus, sirolimus, everolimus, cisapride)
3. Desloratadine
18. Clinically significant abnormalities on ECG repolarization (QTcF \> 450 ms in males and \>470 ms in females) at Screening.
19. Loss of 250 mL or more blood within 3 months prior to screening.
For participants with mild, moderate or severe renal impairment the additional criteria must not be met:
20. Fluctuating or rapidly deteriorating renal function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of renal impairment within the Screening Period.
21. Participants requiring dialysis.
22. History or clinical evidence of any disease (except for renal impairment) and/or existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism or excretion of rupatadine, and/or the ability to complete the study.
For participants with normal renal function, the additional criteria must not be met:
23. History or presence of a clinically relevant abnormality in any organ system, that is incapacitating, requires hospitalization, or in the opinion of the investigator makes the participant ineligible for enrollment in the study.
24. History or clinical evidence of any disease and/or existence of any surgical or medical condition that might have interfered with the absorption, distribution, metabolism, or excretion of rupatadine (appendectomy and herniotomy are allowed, cholecystectomy is not allowed).
25. Intake of any prescribed medication (including vaccines) including over-the-counter (OTC) medication (including herbal and dietary supplements such as St John's Wort, homeopathic preparations, vitamins and minerals) that could affect the outcome of the study as judged by the Investigator, within 14 days before the administration of the IMP or less than 5 times the half-life of that medication, whichever is longer (excluding contraceptives and hormone replacement therapy).
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Noucor Health S.A.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Serafim Guimarães
Role: PRINCIPAL_INVESTIGATOR
Blueclinical Investigacao E Desenvolvimento Em Saude Lda.
Rosa Maria Príncipe, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Pedro Hispano
Daniela Machado Lopes, MD
Role: PRINCIPAL_INVESTIGATOR
Centro Hospitalar de Vila Nova de Gaia/Espinho
Dolores Ochoa Mazarro, MD
Role: PRINCIPAL_INVESTIGATOR
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Ana Maria Aldea Perona, MD
Role: PRINCIPAL_INVESTIGATOR
Municipal Institute Of Medical Investigation
Jordi Soler Majoral, MD
Role: PRINCIPAL_INVESTIGATOR
Germans Trias i Pujol Hospital
Rosa Maria Antonijoan Arbós, MD
Role: PRINCIPAL_INVESTIGATOR
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro Hospitalar De Vila Nova De Gaia Espinho
Gaia, , Portugal
Site Status
RECRUITING
Hospital Pedro Hispano
Matosinhos Municipality, , Portugal
Site Status
RECRUITING
Blueclinical Investigacao E Desenvolvimento Em Saude Lda.
Porto, , Portugal
Site Status
RECRUITING
Hospital Universitari Germans Trias I Pujol
Badalona, , Spain
Site Status
RECRUITING
Municipal Institute Of Medical Investigation
Barcelona, , Spain
Site Status
RECRUITING
Hospital De La Santa Creu I Sant Pau
Barcelona, , Spain
Site Status
RECRUITING
Hospital Universitario De La Princesa
Madrid, , Spain
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Portugal
Spain
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Daniela Machado Lopes, MD
Role: primary
+351227865100
Rosa Maria Príncipe
Role: primary
Jordi Soler Majoral
Role: primary
+34628920023
Ana Maria Aldea Perona, MD
Role: primary
Rosa Maria Antonijoan Arbós
Role: primary
Dolores Ochoa Mazarro
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Billah MM, Chapman RW, Egan RW, Gilchrest H, Piwinski JJ, Sherwood J, Siegel MI, West RE Jr, Kreutner W. Sch 37370: a potent, orally active, dual antagonist of platelet-activating factor and histamine. J Pharmacol Exp Ther. 1990 Mar;252(3):1090-6.
Reference Type
BACKGROUND
Eiser NM, Mills J, Snashall PD, Guz A. The role of histamine receptors in asthma. Clin Sci (Lond). 1981 Apr;60(4):363-70. doi: 10.1042/cs0600363.
Reference Type
BACKGROUND
Cuss FM, Dixon CM, Barnes PJ. Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet. 1986 Jul 26;2(8500):189-92. doi: 10.1016/s0140-6736(86)92489-x.
Reference Type
BACKGROUND
Henocq E, Vargaftig BB. Accumulation of eosinophils in response to intracutaneous PAF-acether and allergens in man. Lancet. 1986 Jun 14;1(8494):1378-9. doi: 10.1016/s0140-6736(86)91683-1. No abstract available.
Reference Type
BACKGROUND
Piwinski JJ, Wong JK, Green MJ, Ganguly AK, Billah MM, West RE Jr, Kreutner W. Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines. J Med Chem. 1991 Jan;34(1):457-61. doi: 10.1021/jm00105a069. No abstract available.
Reference Type
BACKGROUND
Prescott SM, Zimmerman GA, McIntyre TM. The production of platelet-activating factor by cultured human endothelial cells: Regulation and function. In Platelet-activating factor and related lipid mediators. Snyder F, Ed. New York: Plenum Press, 1987: 323-340.
Reference Type
BACKGROUND
Katiyar S, Prakash S. Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis. Prim Care Respir J. 2009 Jun;18(2):57-68. doi: 10.3132/pcrj.2008.00043.
Reference Type
BACKGROUND
Mullol J, Bousquet J, Bachert C, Canonica WG, Gimenez-Arnau A, Kowalski ML, Marti-Guadano E, Maurer M, Picado C, Scadding G, Van Cauwenberge P. Rupatadine in allergic rhinitis and chronic urticaria. Allergy. 2008 Apr;63 Suppl 87:5-28. doi: 10.1111/j.1398-9995.2008.01640.x.
Reference Type
BACKGROUND
Queralt M, Brazis P, Merlos M, de Mora F, Puigdemont A. In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm Res. 2000 Jul;49(7):355-60. doi: 10.1007/PL00000216.
Reference Type
BACKGROUND
Merlos M, Ramis I, Balsa D, Queralt M, Brazís P, Puigdemont A. Inhibitory effect of rupatadine on TNF-a release from human monocytes and mast cell lineHMC-1. J.Allergy Clin. Immunol. 2000 105(Suppl.1): S62.
Reference Type
BACKGROUND
Bartra J, Valero AL, del Cuvillo A, Davila I, Jauregui I, Montoro J, Mullol J, Sastre J. Interactions of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006;16 Suppl 1:29-36. No abstract available.
Reference Type
BACKGROUND
del Cuvillo A, Mullol J, Bartra J, Davila I, Jauregui I, Montoro J, Sastre J, Valero AL. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006;16 Suppl 1:3-12. No abstract available.
Reference Type
BACKGROUND
Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;(182):335-60. doi: 10.1007/978-3-540-74806-9_16.
Reference Type
BACKGROUND
Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother. 2006 Oct;7(14):1989-2001. doi: 10.1517/14656566.7.14.1989.
Reference Type
BACKGROUND
Izquierdo I, Merlos M, Garcia-Rafanell J. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc). 2003 Jun;39(6):451-68. doi: 10.1358/dot.2003.39.6.799450.
Reference Type
BACKGROUND
Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs. 2007;67(3):457-74. doi: 10.2165/00003495-200767030-00008.
Reference Type
BACKGROUND
European Medicines Agency. Committee for Medicinal Products for Human Use Guidance: Guideline on the Investigation of Drug Interactions. 21 June 2012.
Reference Type
BACKGROUND
Rupatadine Investigator's Brochure, dated 21 Sep 2021.
Reference Type
BACKGROUND
Food and Drug Administration Guidance: Pharmacokinetics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing . September 2020.
Reference Type
BACKGROUND
European Medicines Agency. Committee for Medicinal Products for Human Use Guidance: Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. December 2015.
Reference Type
BACKGROUND
FDA Guidance: Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency-Guidance for Industry, Investigators, and Institutional Review Boards: August 2021.
Reference Type
BACKGROUND
DMID ALCOAC Checklist V2.0 29 January 2020.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://www.medicines.org.uk/emc/product/2501/smpc#gref
Summary of Product Characteristics (SmPC) for rupatadine
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DC09RUP/1/21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Chronic Urticaria - Long Term Assessment of Effects of Rupatadine
NCT02358265
TERMINATED
PHASE3
Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects
NCT00258141
UNKNOWN
PHASE4
Pharmacokinetic Study of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function
NCT02775981
COMPLETED
PHASE1
A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
NCT07091357
RECRUITING
PHASE2
Study on Mastocytosis for Rupatadine Treatment
NCT01481909
COMPLETED
PHASE2/PHASE3
A Study of RO4989991 in Patients With Allergic Rhinitis
NCT01152619
COMPLETED
PHASE1
Study of Stapokibart Injection in Patients With Allergic Rhinitis
NCT06525597
RECRUITING
PHASE2
A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine
NCT01103050
COMPLETED
PHASE2
Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects
NCT00605852
COMPLETED
PHASE1
Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects
NCT00620230
COMPLETED
PHASE1
Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine
NCT00636870
COMPLETED
PHASE4
To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis
NCT00525278
COMPLETED
PHASE3
Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
NCT00575003
COMPLETED
PHASE2
A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts
NCT01012752
UNKNOWN
PHASE3
Roflumilast In-Vitro Basophil Release
NCT00613587
COMPLETED
This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines
NCT03926611
COMPLETED
PHASE2
Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848
NCT00770003
COMPLETED
PHASE1
Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants
NCT02127801
COMPLETED
PHASE1
Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections
NCT03038971
TERMINATED
PHASE1
A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients
NCT03570957
COMPLETED
PHASE1
Study In Adults And Adolescents With Seasonal Allergic Rhinitis.
NCT00225823
COMPLETED
PHASE3
Safety Study of Olopatadine Nasal Spray
NCT00578331
COMPLETED
PHASE3
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis
NCT01160861
COMPLETED
PHASE1
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat
NCT04981717
TERMINATED
PHASE3
Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)
NCT01489020
COMPLETED
PHASE1